The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Risks with moving IO to earlier settings in dMMR/MSI-H mCRC
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the potential risks of moving immunotherapy (IO) into earlier, curative settings in deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC), highlighting the increased opportunity to offer treatment to more patients with MSI-H status. Dr Lonardi notes that a potential risk in the adjuvant setting is the possibility of over-treating a proportion of patients due to inadequate staging of the primary tumor, but believes the benefits of immunotherapy outweigh this risk. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
